Researchers at Stanford have developed a unified, AI-augmented governance platform purpose-built for the clinical, research, and educational operations of academic medical centers (AMCs).
Stanford researchers have designed a microfluidic method for improved control of chemical reactions on-chip using isotachophoresis (ITP). This method allows for simultaneous reaction and separation of reaction products and/or reactants.
An interdisciplinary team of Stanford researchers has developed a novel microfluidic technique to extract and purify RNA, DNA or proteins directly from cell lysate.
Researchers in Prof. Juan Santiago's laboratory have developed a modular on-chip isotachophoresis (ITP) system to extend ITP capabilities to include sensitive and selective extraction of nucleic acids.
Researchers at Stanford have developed orthoTeplizumab, an antibody that selectively recognizes engineered T cells without binding a patient's own T cells.
Researchers at Stanford have developed anti-idiotypic antibodies that reverse anti-CD3 monoclonal antibody therapy, giving clinicians control over the depth and timing of T cell depletion before adoptive cell therapy.
Stanford scientists have developed a microfluidic device that uses isotachophoresis to automate every step of nucleic acid testing, from raw sample to readout, and to run multiple reactions in parallel on a single chip with no moving parts.
Researchers at Stanford have developed a novel multi-specific antibody construct that precisely targets and eliminates diseased blood stem cells, offering a less toxic alternative to the chemotherapy and radiation currently used to prepare patients for stem cell transplantatio
Stanford researchers have developed a metal water jet nozzle that enables laser-generated MeV ion beams. When paired with a laser system, the technology could enable more compact, cost-effective medical isotope production and other ion-beam applications.
Researchers at Stanford have developed a three-dimensional human joint organoid platform designed to more accurately model joint tissue biology for musculoskeletal diseases, including osteoarthritis and osteonecrosis.
Researchers at Stanford have developed a blood test technology that detects multiple types of cancer signals at once, using a single, streamlined workflow.
Large-scale, granular biological datasets such as proteomic, metabolomic, and transcriptomic profiles are powering the current shift toward precision medicine.
Stanford scientists have developed CSF-Seq, a whole-transcriptome sequencing platform that reads cell-free RNA in cerebrospinal fluid to enable minimally invasive molecular profiling of neurological and neuro-oncologic disease, including leptomeningeal disease.